The FDA has extended its review of zenocutuzumab's in NRG1+ NSCLC and PDAC to February 2025, with efficacy and safety data ...

Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic ...

In an interview, Colton Ladbury, MD, discussed new insights from a study and expanded on total marrow irradiation’s potential ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Partow Kebriaei, MD, discusses when the optimal time for transplant is in patients with acute lymphoblastic leukemia.

Panelists discuss how they collaborate with community oncology centers when receiving patient referrals for initial or ...

Panelists discuss how to operationalize bispecific antibody (BsAb) therapy in community practices, summarizing the toxicities ...

Dr Graff discusses her standard approach when initiating bispecific antibody treatment for patients, including whether to ...

Dr Graff discusses perceptions of the future for patients treated with bispecific antibodies for non-Hodgkin lymphoma, ...

Dr Graff discusses how to operationalize bispecific antibody (BsAb) therapy in community practices by summarizing the ...

Dr Graff discusses the recommendations for identifying, evaluating, and managing neurological toxicities, including workup ...

Panelists discuss the recommendations for identifying, evaluating, and managing neurological toxicities, including workup and ...